New Data Confirms 340B Hospitals Pocket Discounts While Driving Patients into Debt

The federal 340B Drug Pricing Program was created in 1992 with a noble aim: to help safety-net hospitals stretch scarce federal resources and provide affordable outpatient medications to low-income, uninsured, and vulnerable patients. More than 30 years later, the program has ballooned into an $81.4 billion healthcare monstrosity that functions less like a charitable safety net and more like a slush fund for massive tax-exempt hospital networks. 

For years, the Taxpayers Protection Alliance (TPA) has sounded the alarm on how large nonprofit hospital systems exploit 340B discounts to pad their bottom lines at the expense of American taxpayers and patients. Now, a revealing study published by Temple University’s Center for Public Health Law Research, using a cross-sectional dataset from LawAtlas, makes clear that millions of Americans pay the price for this mission creep and lack of oversight. 

The study examined the Financial Assistance Policies (FAPs) and debt collection practices of 75 of the highest-revenue 340B hospitals in the United States. Because these multi-million-dollar entities enjoy lucrative tax exemptions and receive steep government-mandated drug discounts (often between 20 percent and 50 percent off wholesale rates) it is assumed their financial aid policies are transparent and targeted to ease patient burdens. The data proves otherwise. The study reveals a troubling and largely unscrutinized landscape of barriers to charity care. Shockingly, only 13 of the 75 high-revenue hospitals explicitly detailed any pharmaceutical assistance within their FAPs. More than 80 percent of the 340B hospitals analyzed did not include information about prescription drug assistance in their financial assistance policies, and 31 hospitals did not clearly explain how patients could appeal a denial of financial assistance. If 340B savings were truly being used to aid “vulnerable populations,” multi-billion-dollar hospitals wouldn’t go to such lengths to obscure prescription drug assistance from the public; they would try to make that information accessible. 

Data from the report aligns with other empirical findings. In the Temple University findings, 39 hospitals specified absolutely no limits on collections, and only 6 prohibited “extraordinary collection actions.” This aligns with broader national data compiled by groups such as the National Consumers League, which found that 340B hospitals are significantly more likely to take legal action or deny care due to unpaid bills than non-participating facilities. It’s ironic that a federal program designed to make healthcare affordable is subsidizing nonprofit hospitals that exploit federal rules for profit, then turn around and sue the low-income patients they were meant to serve. 

When large hospital systems manipulate federal programs to maximize revenue, taxpayers lose twice. First, this systemic lack of accountability drives up healthcare costs across the board. The Congressional Budget Office has explicitly confirmed that 340B expansion “encourages behaviors that tend to increase federal spending and inflates costs for state programs, Medicaid, and employer-backed health plans.”

Second, taxpayers must fund the regulatory failures of a system entirely unmoored from accountability. By allowing large urban networks to exploit rural referral loopholes and use contract pharmacy middlemen, billions of dollars are diverted away from public benefit into private bottom lines. 

Instead of state-level band-aids that codify or protect this broken program, Congress must step in with a comprehensive federal overhaul to restore the 340B program’s integrity. True reform must start with codifying into law a clear definition of an eligible “patient.” Hospitals must also be required to report their exact 340B revenues. Healthcare facilities should be in the business of helping people and providing aid and comfort to patients, not driving them into financial ruin using government-mandated discounts.